Oxeltis and Molecular Forecaster Inc. (MFI), a computational chemistry company, announced a strategic partnership, leveraging the strengths of both organizations to offer the seamless integration of in silico design with high-quality chemical synthesis.
Both Oxeltis and MFI focus on accelerating the preclinical stages of the drug design process. Oxeltis proposes services in medicinal and fine organic chemistry for life science research, including hit to pre-clinical candidate optimization, custom synthesis and early scale-up route scouting. MFI is a research-as-a-service (RaaS) organization combining human expertise and proprietary technology that integrates chemistry and computational modeling to reduce design cycles in small molecule campaigns.
“This collaboration is an opportunity to integrate critical research activities from companies with highly specialized and complementary research expertise, and a proven and productive working relationship,” said Jean-Marc Allaire, CEO of Oxeltis. “Whether organizations need virtual screening campaigns, synthesis of focused libraries or fully integrated support for early discovery programs, our combined knowledge and approach enable us to customize innovative and efficient solutions that can create the greatest success for clients.”
“At MFI, we believe the primary benefit of computational drug design is to help humans learn faster so they can make smarter, more strategic decisions that save time, money and lives,” said Josh Pottel, MFI’s CEO. “We also believe collaboration is key to achieving the best possible results. Forming complementary relationships, like this one with Oxeltis, aligns with our values and the way we do business, and we are excited to see where we’ll go together.”
With this collaboration, Oxeltis and MFI will help organizations prioritize candidates, reduce design cycles and boost productivity, by integrating MFI’s predictive modeling and customized, collaborative CADD solutions with Oxeltis’ wet lab-based medicinal chemistry design and synthesis.
The strategic partnership further benefits clients by streamlining project management and administration between the organizations. Clients access competitive cost structures without sacrificing the individual expertise of either team.
The global in silico drug discovery market size was valued at $3.4 billion in 2024 and is predicted to reach $12.8 billion by the year 2034 at a 14.5% CAGR during the forecast period 2025-2034. Preclinical trials are being undertaken at an increasing rate, due to many factors, including the desire for more effective medicines, the increasing complexity of diseases and regulatory restrictions.